Ziccum AB (publ) has appointed Johny Humaloja as its new CFO. Johny is a financial executive with decades of experience in the biopharma and biotech industries in Europe and the US. He will assume his new position on June 15, 2023.

Johny Humaloja has extensive experience as a financial and controller executive in biopharma, biotech and medtech. He has served in senior positions in Europe and the US and is joining Ziccum from the position as CFO of Amniotics AB, where amongst other achievements he led the company through a successful IPO and listing on Nasdaq first north (in 2021). He will assume his new role at Ziccum on June 15th 2023.

Johny has an Executive MBA in Economics & Management from Lund University as well as a BSc in Business Administration & Economics. He brings extensive operational and industrial experience; he has served as a CFO, Financial and Logistics Director, Financial Control Director and as Plant Controller in the US of a large-scale biotech manufacturing facility with an annual budget of USD 110 Million. This is valuable additional expertise for Ziccum, which is taking its unique pharmaceutical drying technology LaminarPace forward to industrialization through international partnering by its licensing business model.

Johny's appointment is part of the dynamic growth and development agenda at Ziccum. The company is currently also seeking to recruit a Chief Operating Officer, with international biopharma experience, as it continues to broaden and strengthen its strategic executive expertise. Ziccum's current CFO, Frida Hjelmberg, will remain in the company for a good transition period.